CINECA IRIS Institutional Research Information System

VALABREGA, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4780
EU - Europa 2916
AS - Asia 1585
OC - Oceania 60
SA - Sud America 60
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 10
Totale 9435
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4656
CN - Cina 917
IT - Italia 794
IE - Irlanda 355
GB - Regno Unito 298
DE - Germania 273
SE - Svezia 272
FR - Francia 223
JP - Giappone 169
VN - Vietnam 116
UA - Ucraina 109
FI - Finlandia 104
CA - Canada 98
ES - Italia 89
IN - India 81
KR - Corea 78
PL - Polonia 74
DK - Danimarca 56
BE - Belgio 55
AU - Australia 51
NL - Olanda 46
TR - Turchia 36
CH - Svizzera 34
TW - Taiwan 31
HK - Hong Kong 30
MX - Messico 25
BR - Brasile 22
AT - Austria 21
PT - Portogallo 21
RO - Romania 20
SG - Singapore 19
TH - Thailandia 19
IR - Iran 18
IL - Israele 17
RU - Federazione Russa 15
AR - Argentina 12
HR - Croazia 11
SA - Arabia Saudita 11
CO - Colombia 9
ID - Indonesia 9
NZ - Nuova Zelanda 9
UZ - Uzbekistan 9
CL - Cile 8
GR - Grecia 8
PE - Perù 8
NO - Norvegia 7
AP - ???statistics.table.value.countryCode.AP??? 6
CZ - Repubblica Ceca 6
HU - Ungheria 6
SN - Senegal 6
BY - Bielorussia 5
MY - Malesia 5
EU - Europa 4
PK - Pakistan 4
SD - Sudan 4
SK - Slovacchia (Repubblica Slovacca) 4
ZA - Sudafrica 4
KW - Kuwait 3
RS - Serbia 3
JO - Giordania 2
LB - Libano 2
MA - Marocco 2
MO - Macao, regione amministrativa speciale della Cina 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
CU - Cuba 1
EC - Ecuador 1
EG - Egitto 1
ET - Etiopia 1
IQ - Iraq 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
NG - Nigeria 1
PH - Filippine 1
QA - Qatar 1
SI - Slovenia 1
ZW - Zimbabwe 1
Totale 9435
Salva come PNG Salva come JPEG
Città #
Chandler 626
Fairfield 448
Houston 345
Dublin 344
Beijing 319
Woodbridge 247
Ann Arbor 237
Ashburn 202
Wilmington 186
Seattle 177
Cambridge 168
Torino 155
Nyköping 137
Redwood City 127
Jacksonville 102
Princeton 91
Medford 90
Villeurbanne 86
Dearborn 85
Munich 79
Shanghai 71
Pisa 67
Guangzhou 66
Dong Ket 64
Warsaw 53
Milan 46
Boston 41
Fremont 41
Tokyo 41
Nanjing 40
London 38
Rome 35
Turin 32
New York 31
Brussels 30
San Diego 28
Wuhan 28
Duncan 27
Chicago 24
Hangzhou 23
Ottawa 22
Toronto 22
Taipei 21
Chengdu 18
Kunming 18
Silver Spring 16
Hebei 14
Phoenix 14
Shenyang 14
Upper Marlboro 14
Vienna 14
Dallas 13
Jinan 13
Seoul 13
Hefei 12
Norwalk 12
Paris 12
Riverton 12
Xian 12
Zhengzhou 12
Madrid 11
Osaka 11
Tianjin 11
Boardman 10
Harbin 10
Newcastle 10
Varese 10
Ankara 9
Basingstoke 9
Central District 9
Changchun 9
Changsha 9
San Francisco 9
Verona 9
Berlin 8
Falls Church 8
Glasgow 8
Hanamkonda 8
Hanoi 8
Helsinki 8
Los Angeles 8
Mexico 8
Nanchang 8
New Delhi 8
Sheffield 8
Toulouse 8
Barcelona 7
Birmingham 7
Central 7
Columbus 7
Hyderabad 7
Montréal 7
Oxford 7
Philadelphia 7
Rochester 7
San Jose 7
Sydney 7
Amsterdam 6
Auckland 6
Buenos Aires 6
Totale 5702
Salva come PNG Salva come JPEG
Nome #
PARP Inhibitors in Ovarian Cancer 1838
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 511
New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer 503
Metastatic breast cancer subtypes and central nervous system metastases. 276
Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. 218
Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity 200
Androgen receptor status predicts development of brain metastases in ovarian cancers 177
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 176
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis 175
p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy 174
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy 162
Adoptive immunotherapy against ovarian cancer 158
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions 149
Immune checkpoint inhibitors: A new opportunity in the treatment of ovarian cancer? 148
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer 140
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. 139
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer? 138
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer 113
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers 111
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience 110
Abstract 3102: Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient-derived xenografts and PDX-derived tumor cells 105
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications 103
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 101
Recent advances in the development of breast cancer vaccines. 100
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer 100
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity 97
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience 97
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy 97
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 96
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series 94
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 92
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 86
Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives 84
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer 83
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma 82
Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models 81
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 79
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer 76
Clinical implications of DNA repair defects in high-grade serous ovarian carcinomas 75
Ovarian cancer immunotherapy: Turning up the heat 75
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 74
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer 68
Identification of Actionable Cancer Genes and Treatment Options for Metastatic Ovarian Carcinomas using Patient Derived Xenografts (PDXs) and PDX Derived Tumor Cells (PDTCs) 67
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial 66
Role of cyclin-dependent kinase inhibitors in endometrial cancer 65
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 63
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 63
A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. 62
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy 62
Is there a role for immunotherapy in ovarian cancer? 61
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. 58
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 58
Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience 58
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer 56
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study 56
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 53
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. 50
Controversies in breast cancer: adjuvant and neoadjuvant therapy 49
Veliparib: a new therapeutic option in ovarian cancer? 49
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers 49
Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents (Scientific Reports, (2019), 9, 1, (3089), 10.1038/s41598-019-39510-w) 49
Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. 48
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era 45
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 43
Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. 41
Translational research in ovarian cancer 41
Trastuzumab-based combination therapy for breast cancer 40
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) 40
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 39
Trastuzumab treatment in breast cancer 37
Biomarkers of central nervous system involvement from epithelial ovarian cancer 37
Potential of afatinib in the treatment of patients with HER2-positive breast cancer. 36
Trastuzumab Beyond Disease Progression: Case Closed? 36
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey 35
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time? 33
Multitarget drugs: the present and the future of cancer therapy 32
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality 32
Immunotherapy in cervix cancer 32
Differences in parp inhibitors for the treatment of ovarian cancer: Mechanisms of action, pharmacology, safety, and efficacy 32
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors 31
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 29
Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. 29
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells 29
Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition 28
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia 27
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 26
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 26
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 26
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? 25
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. 24
Impact of covid-19 in gynecologic oncology: A nationwide italian survey of the sigo and mito groups 16
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey 13
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 13
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer 9
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 5
Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers 5
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 4
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 4
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 3
Totale 9706
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16584
article - articoli 0
book - libri 0
conference - conferenze 525
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17109
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201835 0000 00 00 00035
2018/2019611 26254127 3935 1553 247817375
2019/20201229 494352128 92219 129112 1369367109
2020/20212148 67172270172 175173 157153 178204140287
2021/20222082 149132103161 135144 157170 161148329293
2022/20232323 21122294198 229481 205160 260861770
Totale 9706